Effect of domperidone on QT interval in neonates

Djamal Djeddi1, Guy Kongolo, Charlotte Lefaix

  • 1Department of Pediatrics, School Hospital of Amiens, Amiens, France. djeddi.djamal-dine@chu-amiens.fr

Insights

Oral domperidone can prolong the corrected QT (QTc) interval in infants, particularly those with advanced gestational age and higher serum potassium levels. No ventricular arrhythmias were observed in this study.

Area of Science:

  • Neonatal pharmacology
  • Pediatric cardiology
  • Clinical electrocardiology

Background:

  • Domperidone is frequently used in neonates and infants.
  • Potential cardiac side effects of domperidone require investigation.

Purpose of the Study:

  • To assess the association between oral domperidone and QT interval prolongation in neonates and infants.
  • To identify factors influencing domperidone-induced QTc changes.
  • To evaluate the risk of ventricular arrhythmia with domperidone use.

Main Methods:

  • Electrocardiogram (ECG) performed before and after oral domperidone administration.
  • 31 neonates and infants were studied, categorized by gestational age.
  • Analysis included univariate and multivariate assessments of influencing factors.

Main Results:

  • Oral domperidone was associated with QTc prolongation (mean 14 msec) in infants with gestational age ≥ 32 weeks.
  • Gestational age and serum potassium were identified as risk factors on univariate analysis.
  • Serum potassium was the sole independent predictor of QTc prolongation on multivariate analysis.
  • No ventricular arrhythmias were detected during the study.

Conclusions:

  • Oral domperidone therapy is significantly associated with QTc prolongation in infants.
  • Advanced gestational age and elevated serum potassium are key risk factors.
  • Pre- and post-treatment QT interval measurements are recommended for infants receiving oral domperidone.
Abstract

Related Concept Videos

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship01:14

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...